Abstract
Background Abnormal neurotransmitter levels have been reported in subjects at high risk for schizophrenia, leading to a shift in the excitatory/inhibitory balance. However, it is unclear if these alterations are predating the onset of clinically relevant symptoms. Our aim was to explore in vivo measures of excitatory/inhibitory balance in 22q11.2 deletion carriers, a population at high genetic risk for psychosis.
Methods Glx (glutamate + glutamine) and GABA+ concentrations were estimated in the anterior cingulate cortex (ACC), superior temporal gyrus (STG) and hippocampus using a MEGAPRESS sequence and the Gannet toolbox in 52 deletion carriers and 42 controls. T1-weighted images were acquired longitudinally and processed with Freesurfer v.6.0 to extract hippocampal volume. Subgroup analyses were conducted in deletion carriers with psychotic symptoms identified by means of SIPS.
Results While no differences were found in the ACC, deletion carriers had higher levels of Glx in the hippocampus and STG, and lower levels of GABA+ in the hippocampus compared to controls. We additionally found a higher Glx concentration in the hippocampus of psychotic compared to non-psychotic deletion carriers. Finally, more pronounced hippocampal atrophy and increased functional variability were both significantly associated with increased Glx levels in deletion carriers.
Conclusions This study provides evidence for an excitatory/inhibitory imbalance in temporal brain structures of deletion carriers, with a further hippocampal Glx increase in individuals with psychotic symptoms that was associated with hippocampal atrophy and abnormal function. These results support theories proposing abnormally enhanced glutamatergic neural transmission as a mechanistic explanation for hippocampal atrophy via excitotoxicity. Overall, our results highlight a central role of glutamate in the hippocampus of individuals at genetic risk for schizophrenia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by research grants from the Swiss National Science Foundation (grants 324730-144260 and 320030-179404 to Dr. Eliez) and a National Center of Competence in Research Synapsy grant (grant 51NF40-185897 to Dr. Eliez).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the cantonal ethics committee of Geneva for research
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Corrected typos and a wrong values in the description of the MRI sequence parameters
Data Availability
All data produced in the present study are available upon reasonable request to the authors